Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib

Sunitinib, a multitargeted tyrosine-kinase inhibitor, extends survival of patients with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumours. Between October 2005 and March 2007, we retrospectively reviewed blood glucose level variations associated with sunitinib therapy in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Billemont, B, Medioni, J, Taillade, L, Helley, D, Meric, J B, Rixe, O, Oudard, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579676/
https://www.ncbi.nlm.nih.gov/pubmed/18841151
http://dx.doi.org/10.1038/sj.bjc.6604709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579676/
https://www.ncbi.nlm.nih.gov/pubmed/18841151
http://dx.doi.org/10.1038/sj.bjc.6604709

Ejemplares similares